SP187 (UV-4) is evaluated in vitro for its antiviral efficacy against EBOV and MARV using a yield-plaque assay format. SP187 demonstrates antiviral activity with IC50 values of 29.97 μM and 47.72 μM against EBOV and MARV, respectively.[1]

In this study, C57Bl/6 mice are administered 10 or 100 mg/kg of SP187 or UV-5 via oral gavage or IP injection. Dosing started ~1h before infection with ~1000 pfu of mouse-adapted EBOV and is repeated BID for 10 days at approximately 12-hour intervals for UV-5 or TID at approximately 8-hour intervals for SP187. The selected doses and schedules are based on tolerability studies in naïve mice. No efficacy is observed in the iminosugar-treated mice as compared to the vehicle control.[1]